Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1996-12-30
1998-08-18
Weddington, Kevin E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514178, 514181, 5142315, 514402, 514651, 514653, 514879, 514909, A61K 3156, A61K 31495, A61K 31415, A61K 31135
Patent
active
057958807
ABSTRACT:
The invention describes a method and composition for treating obesity or related disorders in animals using an anorectic agent and dehydroepiandrosterone (DHEA). The composition effectively diminishes caloric intake, may alter metabolism, weight gain, or a combination thereof.
REFERENCES:
patent: 2408345 (1946-09-01), Shelton et al.
patent: 3001910 (1961-09-01), Schutte
patent: 3198833 (1965-08-01), Beregi et al.
patent: 3520975 (1970-07-01), Alphin et al.
patent: 3622675 (1971-11-01), Koppe et al.
patent: 3930009 (1975-12-01), Timms
patent: 3968245 (1976-07-01), Higuchi
patent: 4255439 (1981-03-01), Cooper
patent: 4416894 (1983-11-01), Woodhouse
patent: 4452815 (1984-06-01), Wurtman et al.
patent: 4518595 (1985-05-01), Coleman et al.
patent: 4557934 (1985-12-01), Cooper
patent: 4594358 (1986-06-01), Hynes
patent: 4626549 (1986-12-01), Molloy et al.
patent: 4666898 (1987-05-01), Coleman et al.
patent: 4839382 (1989-06-01), Maestrone et al.
patent: 4871726 (1989-10-01), Applezweig et al.
patent: 4895845 (1990-01-01), Seed
patent: 4897390 (1990-01-01), Ruhe
patent: 4898694 (1990-02-01), Schwartz et al.
patent: 4940585 (1990-07-01), Hapworth et al.
patent: 4956532 (1990-09-01), Robertson et al.
patent: 4978532 (1990-12-01), El-Rashidy
patent: 5001119 (1991-03-01), Schwartz et al.
patent: 5006517 (1991-04-01), Bradlow et al.
patent: 5019594 (1991-05-01), Wurtman et al.
patent: 5096712 (1992-03-01), Wurtman
patent: 5157031 (1992-10-01), Schwartz et al.
patent: 5527788 (1996-06-01), Svec et al.
Bray, "The Zucker-Fatty Rat: A Review," Federation Proceedings, 36, pp. 148-153 (1977).
Cleary, "The Antiobesity Effect of Dehydroepiandrosterone In Rats," Proc. Soc. Exp. Biol. Med., 196, pp. 8-16 (1991).
Darga et al. "Fluoxetine's Effect on Weight Loss In Obese Subjects," The American Journal of Clinical Nutrition, 54, pp. 321-325 (1991).
Gray et al., "A Randomized Double-Blind Clinical Trial of Fluoxetine In Obese Diabetics," International Journal of Obesity, 16, pp. S67-S72 (1992).
McGuirk et al., "Effects of Chronically Administered Fluoxetine and Fenfluramine on Food Intake, Body Weight and The Behavioral Satiety Sequence," Psychopharmacology, 106, pp. 401-407 (1992).
Pomerleau et al., "Effects of Fluoxetine on Weight Gain and Food Intake In Smokers Who Reduce Nicotine Intake," Psychoneuroendocrinology, 16, pp. 433-440 (1991).
Visser et al., "The Effect of Fluoxetine on Body Weight, Body Composition and Visceral Fat Accumulation," International Journal of Obesity, 17, pp. 247-253 (1993).
White et al., "Responsiveness of Isolated Adrenocortical Cells From Lean And Obese Zucker Rats to ACTH," Am. J. Physiol., 225, pp. E229-E235 (1988).
Wright et al., "Divergent Effect of Dehydroepiandrosterone On Energy Intakes of Zucker Rats," Physiology & Behavior, 53, pp. 39-43 (1993).
Garattini et al., "From Fenfluramine Racemate To d-Fenfluramine," Annals Of The New York Academy of Sciences, 499, Human Obesity, Wurtman et al., eds., pp. 156-166 (1987).
Physicians' Desk Reference, 47th Edition, pp. 710-711, 857-858, 943-946, 1053, 1403-1404, 1949-1950, 2126-2127, 2305-2306 (Medical Economics Data, NJ, (1993).
Abadie et al., "Effect of Dehydroepiandrosterone On Neurotransmitter Levels and Appetite Regulation of the Obese Zucker Rat," Diabetes, 42, pp. 662-669 (1993).
Browne et al., "Dehydroepiandrosterone: Antiglucocorticoid Action In Mice," Am. J. Med. Sci., 303, pp. 366-371 (1992).
Wright et al., "Antiglucocorticoid Action of Dehydroepiandrosterone In Young Obese Zucker Rats," Int. J. Of Obesity, 16, pp. 579-583 (1992).
Van de Kar et al., "Serotonergic Neurons and Neuroendocrine Function," NIPS, 8, pp. 202-207 (1993).
Abadie et al., "Effects of Dehydroepiandrosterone And/Or Fenfluramine On Macronutrient Selection and Hypothalamic Neurotransmitter Content In Zucker Rats," Fed Am Soc Exp Biol. J., 7, A413 (1993).
Porter et al., "Fenfluramine FF Effects on Brain 5-Hydroxytryptamine 5-HT and 5-Hydroxyindoleacetic Acid 5-HIAA In the Obese Zucker Rat," Fed Am Soc Exp Biol. J., 4, A376 (1990).
Hargrave et al., "Delta-4-Androstenedione and Feeding Inhibition In the Lean and Obese Zucker Rat," Clinical Research, 41, A756 (1993).
Cleary, "The Autiobesity Effect of Dehydroepiandrosterone In Rats," Proc. Soc. Exp. Biol. Med; 196 pp. 8-16 (1991).
Visser et al., "The Effect pf Fluoretine On Body Weight; Body Composition and Visceral Fat Accumuletis," International Journal of Obesity, 17, pp. 247-253 (1993).
Porter Johnny
Svec Frank
Louisiana State University Medical Center Foundation
Weddington Kevin E.
LandOfFree
Method and composition for treating obesity and related disorder does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and composition for treating obesity and related disorder, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and composition for treating obesity and related disorder will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1114888